This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| National Imaging Facility | |
|---|---|
| Name | National Imaging Facility |
National Imaging Facility is a distributed Australian research infrastructure consortium that provides access to advanced medical and preclinical imaging technologies. It supports translational imaging studies across universities, hospitals, and research institutes, enabling collaborations between clinicians, neuroscientists, oncologists, and biophysicists. The Facility underpins projects spanning clinical trials, basic science, and industry partnerships.
The Facility operates as a networked facility linking major nodes at University of Melbourne, Monash University, University of Sydney, University of Queensland, Australian National University, and partner sites such as Florey Institute of Neuroscience and Mental Health, Garvan Institute of Medical Research, Royal Brisbane and Women's Hospital, and Calvary Mater Hospital. It hosts modalities including magnetic resonance imaging, positron emission tomography, computed tomography, single-photon emission computed tomography, optical imaging (biophotonics), and preclinical micro-imaging systems used in studies involving Alzheimer's disease, Parkinson's disease, multiple sclerosis, breast cancer, and prostate cancer. The Facility provides infrastructure access to researchers funded through schemes such as the Australian Research Council and the National Health and Medical Research Council, and supports industry collaborations with multinational companies and small-to-medium enterprises.
The Facility was established in response to national strategic reviews and roadmaps including recommendations from the National Collaborative Research Infrastructure Strategy, and followed precedent models like the Australian Synchrotron and the Australian Research Data Commons. Early consortia formed with nodes at institutions such as University of New South Wales, Deakin University, and James Cook University. Key developmental milestones involved procurement of high-field scanners comparable to installations at Massachusetts General Hospital and Johns Hopkins Hospital, participation in multicentre trials linked to International Society for Magnetic Resonance in Medicine initiatives, and integration with statewide research hubs such as Queensland Brain Institute and South Australian Health and Medical Research Institute.
Nodes provide a range of instruments: clinical 3T and 7T magnetic resonance imaging scanners, hybrid PET/MRI systems similar to those at Mayo Clinic, high-resolution preclinical micro-CT and micro-PET imagers, and optical imaging suites used in conjunction with facilities like Peter MacCallum Cancer Centre and Children's Medical Research Institute. Each node implements data management systems interoperable with platforms like XNAT and standards advocated by International Organization for Standardization working groups and aligns with protocols from bodies such as Therapeutic Goods Administration for device compliance. Imaging cores are co-located with clinical research units including Royal Melbourne Hospital clinical trial units and pathology services at Victorian Comprehensive Cancer Centre.
Services include project consultation, protocol development, specialist technician support, image processing pipelines employing toolkits such as FSL (software), SPM (software), and FreeSurfer, and radiochemistry for radiotracer production following guidelines from International Atomic Energy Agency. Research outputs span neuroimaging biomarkers for Alzheimer's disease progression, PET ligand development targeting amyloid beta and tau protein, pharmacokinetic imaging in oncology trials involving agents evaluated at Peter MacCallum Cancer Centre, and preclinical disease models hosted with partners like Walter and Eliza Hall Institute of Medical Research. Training programs run with institutions including University of Western Australia and Swinburne University of Technology to build capacity in imaging physicists, radiochemists, and clinician-scientists.
The Facility partners with major research institutes, health services, and industry. Strategic collaborations include joint projects with CSIRO, translational research programs at Garvan Institute of Medical Research, and multicentre clinical trials coordinated with networks such as Australian Clinical Trials Alliance. International linkages extend to consortia involving European Organisation for Research and Treatment of Cancer, National Institutes of Health (United States), and academic hubs at University College London and Karolinska Institutet. Cooperative agreements with radiopharmaceutical producers and medical imaging vendors such as Siemens Healthineers, GE Healthcare, and Philips facilitate technology access and method validation.
Governance is delivered through a consortium board including representatives from member universities and health partners, drawing on expertise from leaders affiliated with Monash Health, Royal Prince Alfred Hospital, and major research institutes. Funding sources combine competitive grants from the National Health and Medical Research Council, infrastructure investment via the Australian Government Department of Education, Skills and Employment initiatives, state research infrastructure programs, and cost-recovery from industry contracts. Oversight frameworks align with ethics review processes run by Human Research Ethics Committees at hospitals like St Vincent's Hospital, Sydney and universities such as University of Adelaide.
The Facility has enabled high-impact studies including multicentre neuroimaging consortia on frontotemporal dementia and longitudinal cohorts aligned with programs like the Dominantly Inherited Alzheimer Network style initiatives in Australia. Notable projects include PET tracer trials for amyloid beta detection run with pathology teams at Austin Health, MRI biomarker development for multiple sclerosis tied to clinics at Royal Brisbane and Women's Hospital, and oncology imaging trials informing surgical planning at Peter MacCallum Cancer Centre. The Facility’s infrastructure has supported spin-out technologies commercialized by startups incubated at CIC bioGUNE-like environments and contributed data to federated repositories similar to OpenNeuro. It continues to be a backbone for translational imaging research across Australian biomedical science.